JNJ

$JNJ

Johnson & Johnson

Diversified healthcare company with pharmaceuticals, medical devices, and consumer products.

Healthcare
$267.14
-5.56 (-2.04%)
Day Range$264.68 - $270.60
Prev Close$272.70

JNJ key facts as of November 14, 2026

Latest AI research report
JNJ Research: Growth, Valuation and Key Risks (as of November 14, 2026)
StockAlpha report sentiment
Neutral (as of November 14, 2026)
Analyst consensus
Strong Buy (5 Strong Buy, 11 Buy, 6 Hold, 1 Sell, 0 Strong Sell) (as of November 1, 2026)
Analyst price target
$285.31 mean (range $260.00 to $320.00) (as of November 20, 2026)
Sector
Healthcare
Analyst Rating
Strong Buy
16 Buy / 6 Hold / 1 Sell
Price Target
$285.31
6.8% upside
Subscribers
0
Tracking this ticker
Latest Report

Analysis from Nov 13, 2026

NEUTRAL

JNJ Research: Growth, Valuation and Key Risks

Johnson & Johnson reported a recent earnings beat and its shares are near a 52-week high, while analyst ratings remain broadly positive. But the mean target is close to the Friday close, and valuation and legal risks remain important parts of the picture.

Nov 14, 2026

JNJ FAQ

What is StockAlpha's latest view on JNJ?

StockAlpha's latest AI research report on Johnson & Johnson (JNJ), "JNJ Research: Growth, Valuation and Key Risks", was published on November 14, 2026 and rates the overall sentiment as neutral. Johnson & Johnson reported a recent earnings beat and its shares are near a 52-week high, while analyst ratings remain broadly positive. But the mean target is close to the Friday close, and valuation and legal risks remain important parts of the picture.

When was the JNJ research last updated?

The most recent JNJ report was published on November 14, 2026.

What do analysts expect for JNJ?

As of November 1, 2026, the analyst consensus on JNJ is Strong Buy (5 Strong Buy, 11 Buy, 6 Hold, 1 Sell, 0 Strong Sell). As of November 20, 2026, the analyst price target is $285.31 mean (range $260.00 to $320.00).

Is this JNJ research investment advice?

No. StockAlpha.ai research is AI-generated analysis for informational purposes only and is not investment advice. Analyst figures are third-party data. Do your own research before making investment decisions.

Keep exploring